FTXH - ETF AI Analysis
Top Page
First Trust Nasdaq Pharmaceuticals ETF (FTXH)
Rating:72Outperform
Price Target:―
Positive Factors
Strong Recent Performance
The ETF has shown strong gains so far this year and over the past few months, which indicates positive recent momentum.
Leading Pharmaceutical Holdings
Many of the top holdings, including well-known drug makers, have delivered solid year-to-date gains that support the fund’s overall results.
Focused Exposure to Health Care
Concentrating almost entirely on U.S. health care companies gives investors targeted access to a major defensive sector tied to long-term demand for medicines.
Negative Factors
High Sector Concentration
With nearly all assets in the health care sector, the fund is vulnerable if pharmaceuticals or health care stocks fall out of favor.
Limited Geographic Diversification
Almost all holdings are U.S.-based, so investors get little protection from markets in other regions if the U.S. market weakens.
Above-Average Expense Ratio
The fund’s expense ratio is on the higher side for an ETF, which means more of the returns are used to cover fees instead of staying with investors.
FTXH vs. SPDR S&P 500 ETF (SPY)
AUM1.05B
RegionNorth America
Expense Ratio0.60%
Beta0.47
IssuerFirst Trust
Inception DateSep 20, 2016
Dividend Yield1.04%
Asset ClassEquity
Index TrackedNasdaq US Smart Pharmaceuticals Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume22,514
30 Day Avg. Volume614,623
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
45.69Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering49
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
FTXH Summary
FTXH is the First Trust Nasdaq Pharmaceuticals ETF, which follows the Nasdaq US Smart Pharmaceuticals Index. It focuses on U.S. drugmakers and health care companies, holding well-known names like Eli Lilly and Johnson & Johnson. This fund gives investors a simple way to invest in the growth of new medicines, treatments, and drug research without having to pick individual stocks. Someone might choose this ETF for targeted exposure to the pharmaceutical industry and potential long-term growth. However, it is heavily concentrated in health care and drug companies, so its price can swing with changes in drug approvals, regulation, and the overall stock market.
How much will it cost me?The First Trust Nasdaq Pharmaceuticals ETF (FTXH) has an expense ratio of 0.6%, meaning you’ll pay $6 per year for every $1,000 invested. This is higher than average because it is actively managed and focuses on a specialized sector, which typically involves more research and management costs.
What would affect this ETF?The FTXH ETF could benefit from advancements in pharmaceutical research, including breakthroughs in drug development and personalized medicine, as well as increased demand for innovative health care solutions in the U.S. However, it may face challenges from regulatory changes, patent expirations, or economic downturns that could impact the profitability of its top holdings like AbbVie, Johnson & Johnson, and Merck.
FTXH Top 10 Holdings
FTXH is essentially a who’s who of U.S. Big Pharma, with Merck, AbbVie, Johnson & Johnson, Bristol-Myers Squibb, and Amgen setting the tone. Merck and Amgen have been rising steadily, acting as key engines for the fund, while Johnson & Johnson and Bristol-Myers add solid, if less flashy, support. Eli Lilly’s more mixed, recently losing a bit of steam, and Viatris has been lagging, slightly dragging on returns. With nearly all exposure in U.S. health care and a tight focus on pharmaceuticals, this ETF is a concentrated bet on drugmakers’ pipelines and pricing power.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Merck & Company | 7.53% | $78.35M | $355.10B | 73.81% | 80 Outperform | |
| AbbVie | 7.18% | $74.68M | $454.36B | 17.76% | 66 Neutral | |
| Johnson & Johnson | 6.93% | $72.08M | $640.02B | 49.15% | 78 Outperform | |
| Eli Lilly & Co | 6.85% | $71.26M | $1.05T | 47.70% | 72 Outperform | |
| Bristol-Myers Squibb | 6.61% | $68.79M | $130.00B | 37.75% | 78 Outperform | |
| Biogen | 3.66% | $38.14M | $32.08B | 49.90% | 74 Outperform | |
| Viatris | 3.58% | $37.28M | $18.96B | 65.76% | 60 Neutral | |
| Vertex Pharmaceuticals | 3.37% | $35.04M | $130.64B | 30.65% | 78 Outperform | |
| Cardinal Health | 3.32% | $34.55M | $54.56B | 54.08% | 66 Neutral | |
| Regeneron | 3.25% | $33.80M | $80.46B | 39.55% | 78 Outperform |
FTXH Technical Analysis
Positive
―
Price Trends
40.07
Positive
37.65
Positive
35.69
Positive
Market Momentum
0.16
Positive
50.13
Neutral
19.33
Positive
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For FTXH, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 41.55, equal to the 50-day MA of 40.07, and equal to the 200-day MA of 35.69, indicating a neutral trend. The MACD of 0.16 indicates Positive momentum. The RSI at 50.13 is Neutral, neither overbought nor oversold. The STOCH value of 19.33 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FTXH.
FTXH Peer Comparison
Comparison Results
Performance Comparison
FTXH
First Trust Nasdaq Pharmaceuticals ETF
40.83
13.21
47.83%
IYH
iShares U.S. Healthcare ETF
―
―
―
FHLC
Fidelity MSCI Health Care Index ETF
―
―
―
IHI
iShares U.S. Medical Devices ETF
―
―
―
FBT
First Trust NYSE Arca Biotechnology Index Fund
―
―
―
IHE
iShares U.S. Pharmaceuticals ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents